ACAD: ACADIA Pharmaceuticals Inc - zacks.com ACAD: ACADIA Pharmaceuticals Inc broker recommendations. Get the latest broker recommendations from Zacks Investment Research. ACAD: ACADIA Pharmaceuticals Inc - Zacks Investment Research ACAD: ACADIA Pharmaceuticals Inc broker recommendation chart. Get the latest chart with broker recommendations from Zacks Investment Research. Should I buy Acadia Pharmaceuticals Inc. (ACAD) - Zacks Zacks' proprietary data indicates that ACADIA Pharmaceuticals Inc. is currently rated as a Zacks Rank 3 and we are expecting an inline return from the ACAD shares relative to the market in the next Partner News For ACAD - Zacks Investment Research
Davis Stephen: CEO: 05/14/2020: DS: Direct: COM: 4,321: $45.01: $194,508.95: 11,809: Davis Stephen: CEO: 05/14/2020: DS: Direct: COM: 84,221: $45.65: $3,844,596.01
ACAD: ACADIA Pharmaceuticals Inc - Earnings Announcements. Stay up to date with lastest Earnings Announcements for ACADIA Pharmaceuticals Inc from Zacks Investment Research Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results. ACAD: ACADIA Pharmaceuticals Inc broker recommendation chart. Get the latest chart with broker recommendations from Zacks Investment Research. Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.
What Makes Acadia Pharmaceuticals (ACAD) a Strong …
ACAD | Complete ACADIA Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Find the latest ACADIA Pharmaceuticals Inc. (ACAD) stock quote, history, news and other vital information to help you with your stock trading and investing. The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.. The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of ACAD: Get the latest ACADIA Pharmaceuticals stock price and detailed information including ACAD news, historical charts and realtime prices. What happened. Shares of mid-cap drugmaker Acadia Pharmaceuticals (NASDAQ:ACAD) rose by as much as 13% in pre-market trading today. The biopharma's stock is jumping in response to a presentation
Anaplan, Inc. is expected* to report earnings on 05/26/2020 before market open. The report will be for the fiscal Quarter ending Apr 2020. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.3. The reported EPS for the same
Stocks Analysis by Zacks Investment Research covering: Amgen Inc, ACADIA Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc, Incyte Corporation. Read Zacks Investment Research's latest article on SAN DIEGO (AP) _ Acadia Pharmaceuticals Inc. (ACAD) on Wednesday reported a loss of $42 million in its third quarter. The San Diego-based company said it had a loss of 29 cents per share. The results topped Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of 41 cents per share. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.41. The reported EPS for the same quarter last year was $-0.39. Twilio last announced its earnings results on February 5th, 2020.
ACAD Stock Price, Forecast & News (ACADIA Pharmaceuticals)
It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Acadia Pharmaceuticals Bottom Line. Given these factors, it shouldn't be surprising that ACAD is a #2 (Buy) stock and boasts a Momentum Score of A. If you're looking for a fresh pick that's set to soar in the near-term The Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us. Below, we take a look at Acadia Pharmaceuticals (ACAD) , which currently has a Momentum Style Score ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.